Pod24 and Cr30 Are Promising Surrogate Endpoints for Assessing the Outcome of Patients With Advanced Stage Follicular Lymphoma Enrolled in the Foll05 Trial by Fil.

Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_91

Related search